Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)

AI-QCT/AI-CPA using CCTA is medically necessary for patients with acute or stable chest pain without known CAD who are eligible for CCTA and whose cardiac evaluation is negative or inconclusive for ACS, when CCTA shows intermediate clinical risk or CAD-RADS 1–3. The test must be performed only after a completed and interpreted CCTA using FDA-cleared/approved software and interpreted by appropriately trained and credentialed providers; it is not covered for screening, post-MI within 30 days, unstable symptoms, surveillance, high-grade stenosis (CAD-RADS 4–5), normal CCTA (CAD-RADS 0), or when CCTA is contraindicated.

"Patient with acute or stable chest pain, no known coronary artery disease (no prior anatomic testing showing plaque or obstructive CAD), who is eligible for CCTA per policy L33947, and whose cardia..."

Sign up to see full coverage criteria, indications, and limitations.